The 340B program spent $43.9 billion in 2021, supporting nearly 50,000 hospitals with discounted outpatient drugs. Cancer drugs constitute 41% of 340B purchases, with outpatient departments and ...

The Patient Protection and Affordable Care Act is expected to bring significant change to the healthcare industry, including the expansion of the Public Health Service Act Section 340B Program.

Senator calls on Congress to increase oversight of the 340B Drug Pricing Program by requiring participating providers to complete annual reports on program savings and revenues. If your health system ...

The 340B Program has continued to undergo significant upheaval in 2024 that has the potential to bring about impactful changes to how the 340B Program operates moving forward. These developments have ...

Mere days before the Health Resources and Services Administration’s (HRSA) 340B Rebate Model Pilot Program’s (“Pilot”) scheduled January 1, 2026 effective date, a federal district court granted a ...

Hospitals that serve a high volume of low-income and uninsured patients rely on Disproportionate Share Hospital (DSH) funding to maintain financial stability. A hospital’s DSH percentage is critical ...

The 340B Drug Pricing Program was created to help a targeted group of safety net providers care for low-income and uninsured patients. First enacted as part of the Veterans Healthcare Act of 1992, ...

Six drugmakers who have violated the 340B statute should immediately begin offering drugs at discounted prices to hospitals participating in the federal drug-pricing program, according to a letter ...

Further, 340B impact may vary for different methods of administration within the same indication – for example, Gilead’s expects lower 340B exposure for injectables for PrEP than for daily orals – and ...